Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Growth 2020 | Statistics Revenue, Share, Competitive Landscape Size, Segments, Key Vendors, Emerging Technologies and Forecast to 2026

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological disorder that is known for eventually resulting in paralysis (impairment of sensory function in limbs). It occurs due to the inflammation of nerve roots, peripheral nerves, and destruction of the fatty protective covering (myelin sheath) over the nerves. It slows down the transmission of nerve signals, thus leading to destruction of nerve fibers. It can be treated with corticosteroids or in combination with an immunosuppressant, plasma exchange, and intravenous immunoglobulin therapy.

Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/2609

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Analysis

According to the latest report, increasing drug approvals by regulatory authorities would propel the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, in March 2017, CSL Behring received U.S. Food and Drug Administration (FDA) approval for Privigen, an immunoglobulin therapy for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) disorder. 207 patients were treated with Privigen for 13 weeks and 73% out of these 207 patients responded to it in clinical trials.

Furthermore, in March 2018, CSL Behring received the U.S. FDA approval for Hizentra, which is a type of subcutaneous immunoglobulin therapy that prevents relapsing neuromuscular disability. It offers a convenient treatment type, in which patients can infuse themselves. The approval was based on the phase III results of the clinical trial. Therefore, these factors are likely to provide an impetus to the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth in the coming years.

Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2609

Moreover, there are several potential drugs in the pipeline for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). For instance, in January 2016, Shire Plc, began clinical trials of HyQvia for treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) disorder. HyQvia is a type of intravenous immunoglobulin therapy approved for the treatment of primary immunodeficiency and is currently in phase III of clinical trials for CIDP. Hence, successful clinical trial completion and subsequent launch of these products are expected to boost the global market growth.

Additionally, the introduction of advanced technologies in diagnostic tools for chronic inflammatory demyelinating polyneuropathy (CIDP) disorder is estimated to accelerate the global market expansion. For instance, in July 2018, according to National Centre for Biotechnology Information (NCBI), multifocal visional evoked potential, a technique to diagnose CIDP is capable of detecting abnormalities in the optic nerve fiber, hence ensures higher accuracy in diagnosis. Therefore advancements in diagnostic tools of chronic inflammatory demyelinating polyneuropathy disorder are expected to support the growth of the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/2609

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market – Regional Analysis

North America is expected to hold a dominant position in the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market. Factors such as initiatives from governments and other organizations are expected to have an influence on the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, in April 2019, Guillain-Barre syndrome & Chronic Inflammatory Demyelinating Polyneuropathy (GBS | CIDP) international foundation announced that it is going to celebrate May as GBS | CIDP awareness month. They plan to create awareness about the foundation’s legislative initiatives for CIDP patients through social media and campaigns. The initiative is for creating a bill which includes the establishment of the Medicare Part B Home Infusion Demonstration Project, and increase in funds for treatment of CIDP patients. These factors are expected to have a positive impact on the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth.

Market Restraints

Failure of the drugs in late stages of clinical trials has hampered the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, drugs such as Fingolimod (Gilenya, Novartis AG), and Acthar gel (Mallinckrodt Pharmaceuticals) indicated for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) failed in the clinical trials in 2016, and 2018, respectively. These failures were associated with serious adverse events shown by these medications such as hypertension, extreme pain, fluid retention, alteration in glucose tolerance, and behavioral and mood changes.

Request to download and view full ToC: https://www.coherentmarketinsights.com/ongoing-insight/toc/2609

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market – Key Competitors

Some of the major players operating in the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market include CSL Behring, Kedrion S.p.A., Takeda Pharmaceutical Co. Ltd., Shire Plc., GeNeuro SA, Baxter International Inc., Octapharma AG and Grifols S.A., Teijin Pharma Ltd., and Nihon Pharmaceutical Co. Ltd.

Market Taxonomy

By Treatment Type,

• Intravenous immunoglobulin therapy
  • Privigen
  • Hizentra
  • Gamunex-C
  • Tegeline
  • Others
• Corticosteroids
• Others

By Distribution Channel,

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Region,

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.